↓ Skip to main content

Potential sources of increased iron in the substantia nigra of parkinsonian patients.

Overview of attention for book
Cover of 'Potential sources of increased iron in the substantia nigra of parkinsonian patients.'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Melvin Yahr (1917–2004). An appreciation
  3. Altmetric Badge
    Chapter 2 Melvin D. Yahr, 1917–2004. A personal recollection
  4. Altmetric Badge
    Chapter 3 The discovery of dopamine deficiency in the parkinsonian brain
  5. Altmetric Badge
    Chapter 4 Synchronizing activity of basal ganglia and pathophysiology of Parkinson’s disease
  6. Altmetric Badge
    Chapter 5 Basal ganglia discharge abnormalities in Parkinson’s disease
  7. Altmetric Badge
    Chapter 6 Bad oscillations in Parkinson’s disease
  8. Altmetric Badge
    Chapter 7 Cortical muscle coupling in Parkinson’s disease (PD) bradykinesia
  9. Altmetric Badge
    Chapter 8 GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons
  10. Altmetric Badge
    Chapter 9 The engrailed transcription factors and the mesencephalic dopaminergic neurons
  11. Altmetric Badge
    Chapter 10 The role of Pitx3 in survival of midbrain dopaminergic neurons.
  12. Altmetric Badge
    Chapter 11 Genetic analysis of dopaminergic system development in zebrafish
  13. Altmetric Badge
    Chapter 12 Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease
  14. Altmetric Badge
    Chapter 13 The nigrostriatal DA pathway and Parkinson's disease.
  15. Altmetric Badge
    Chapter 14 Relationship between axonal collateralization and neuronal degeneration in basal ganglia
  16. Altmetric Badge
    Chapter 15 Pathology associated with sporadic Parkinson’s disease — where does it end?
  17. Altmetric Badge
    Chapter 16 Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson’s disease
  18. Altmetric Badge
    Chapter 17 A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease.
  19. Altmetric Badge
    Chapter 18 The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help?
  20. Altmetric Badge
    Chapter 19 New face of neuromelanin
  21. Altmetric Badge
    Chapter 20 The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells
  22. Altmetric Badge
    Chapter 21 Potential sources of increased iron in the substantia nigra of parkinsonian patients
  23. Altmetric Badge
    Chapter 22 Iron and Friedreich ataxia
  24. Altmetric Badge
    Chapter 23 Nongenetic causes of Parkinson’s disease
  25. Altmetric Badge
    Chapter 24 Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae?
  26. Altmetric Badge
    Chapter 25 CYP450, genetics and Parkinson’s disease: gene × environment interactions hold the key
  27. Altmetric Badge
    Chapter 26 Unique cytochromes P450 in human brain: implication in disease pathogenesis
  28. Altmetric Badge
    Chapter 27 Cytochrome P450 and Parkinson’s disease: protective role of neuronal CYP 2E1 from MPTP toxicity
  29. Altmetric Badge
    Chapter 28 Nicotine induces brain CYP enzymes: relevance to Parkinson’s disease
  30. Altmetric Badge
    Chapter 29 Genetic causes of Parkinson’s disease: extending the pathway
  31. Altmetric Badge
    Chapter 30 Progress in familial Parkinson’s disease
  32. Altmetric Badge
    Chapter 31 Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins
  33. Altmetric Badge
    Chapter 32 Parkin and defective ubiquitination in Parkinson’s disease
  34. Altmetric Badge
    Chapter 33 PINK-1 and DJ-1 — new genes for autosomal recessive Parkinson’s disease
  35. Altmetric Badge
    Chapter 34 Clinical and pathologic features of families with LRRK2-associated Parkinson’s disease
  36. Altmetric Badge
    Chapter 35 Molecular genetic findings in LRRK2 American, Canadian and German families.
  37. Altmetric Badge
    Chapter 36 Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort
  38. Altmetric Badge
    Chapter 37 Neuroimaging in Parkinson’s disease
  39. Altmetric Badge
    Chapter 38 Transcranial sonography in the early and differential diagnosis of Parkinson’s disease
  40. Altmetric Badge
    Chapter 39 How to judge animal models of Parkinson’s disease in terms of neuroprotection
  41. Altmetric Badge
    Chapter 40 Limitations of cellular models in Parkinson’s disease research
  42. Altmetric Badge
    Chapter 41 The Rotenone model of Parkinsonism — the five years inspection
  43. Altmetric Badge
    Chapter 42 Controversies on new animal models of Parkinson’s disease Pro and Con: the rotenone model of Parkinson’s disease (PD)
  44. Altmetric Badge
    Chapter 43 Proposed animal model of severe Parkinson’s disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum
  45. Altmetric Badge
    Chapter 44 α-Synuclein overexpression model
  46. Altmetric Badge
    Chapter 45 Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies
  47. Altmetric Badge
    Chapter 46 What’s new? Clinical progression and staging of Parkinson’s disease
  48. Altmetric Badge
    Chapter 47 Parkinson’s disease: premotor clinico-pathological correlations
  49. Altmetric Badge
    Chapter 48 Detection of preclinical Parkinson’s disease along the olfactory trac(t)
  50. Altmetric Badge
    Chapter 49 The clinical approach to gait disturbances in Parkinson’s disease; maintaining independent mobility
  51. Altmetric Badge
    Chapter 50 Getting around and communicating with the environment: visual cognition and language in Parkinson’s disease
  52. Altmetric Badge
    Chapter 51 Cardiovascular aspects of Parkinson disease
  53. Altmetric Badge
    Chapter 52 Multiple system atrophy and autonomic failure
  54. Altmetric Badge
    Chapter 53 Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview
  55. Altmetric Badge
    Chapter 54 Sleep and wakefulness disturbances in Parkinson’s disease
  56. Altmetric Badge
    Chapter 55 Parkinson’s disease dementia: what’s in a Lewy body?
  57. Altmetric Badge
    Chapter 56 Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10
  58. Altmetric Badge
    Chapter 57 Role of cytokines in inflammatory process in Parkinson’s disease
  59. Altmetric Badge
    Chapter 58 Surgical therapy for Parkinson’s disease
  60. Altmetric Badge
    Chapter 59 Deep brain stimulation for the treatment of Parkinson’s disease
  61. Altmetric Badge
    Chapter 60 Deep brain stimulation in Parkinson’s disease patients: biochemical evidence
  62. Altmetric Badge
    Chapter 61 Neurosurgery in Parkinson’s disease: the doctor is happy, the patient less so?
  63. Altmetric Badge
    Chapter 62 Placebo effect and dopamine release
  64. Altmetric Badge
    Chapter 63 A new look at levodopa based on the ELLDOPA study
  65. Altmetric Badge
    Chapter 64 Thirty five years of experience in the treatment of Parkinson’s disease with levodopa and associations
  66. Altmetric Badge
    Chapter 65 Concerning neuroprotective therapy for Parkinson’s disease
  67. Altmetric Badge
    Chapter 66 Triggering endogenous neuroprotective mechanisms in Parkinson’s disease: studies with a cellular model
  68. Altmetric Badge
    Chapter 67 Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression.
  69. Altmetric Badge
    Chapter 68 M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease
  70. Altmetric Badge
    Chapter 69 Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety
  71. Altmetric Badge
    Chapter 70 Anti-apoptotic gene therapy in Parkinson’s disease
  72. Altmetric Badge
    Chapter 71 The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors
  73. Altmetric Badge
    Chapter 72 Pathophysiology of dystonia
  74. Altmetric Badge
    Chapter 73 Genetics of dystonia
Attention for Chapter 24: Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae?
Altmetric Badge

Mentioned by

twitter
6 tweeters
facebook
10 Facebook pages
wikipedia
12 Wikipedia pages

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
54 Mendeley
citeulike
1 CiteULike
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae?
Chapter number 24
Book title
Parkinson’s Disease and Related Disorders
Published by
Springer Vienna, January 2006
DOI 10.1007/978-3-211-45295-0_24
Book ISBNs
978-3-21-128927-3, 978-3-21-145295-0
Authors

Dr. A. Lannuzel, G. U. Höglinger, P. Champy, P. P. Michel, E. C. Hirsch, M. Ruberg, A. Lannuzel

Editors

Prof. Dr. P. Riederer, Prof. Dr. H. Reichmann, Prof. Dr. M. B. H. Youdim, Prof. Dr. M. Gerlach

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 2%
Unknown 53 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 17%
Student > Bachelor 8 15%
Researcher 7 13%
Student > Ph. D. Student 7 13%
Student > Doctoral Student 5 9%
Other 9 17%
Unknown 9 17%
Readers by discipline Count As %
Agricultural and Biological Sciences 14 26%
Medicine and Dentistry 9 17%
Pharmacology, Toxicology and Pharmaceutical Science 7 13%
Biochemistry, Genetics and Molecular Biology 3 6%
Neuroscience 3 6%
Other 7 13%
Unknown 11 20%